




# SEMPP- DUR Board Meeting

February 27, 2019

# SEMPP Prior Authorizations


- 2017
  - ~21% Denial
- 2018
  - ~3% Denial



# Risk Reduction Strategies




	PDMP	Patient Provider Agreement	Risk Screening
<b>% Average for 1<sup>st</sup> 3 Months Of Program</b>	76	65	57
<b>% Average for 2018</b>	94	90	81
<b>% Increase</b>	18	25	24



# Impact on MME/Day

## ■ Limitations

- Inclusion of Cancer related pain requests
- Additional Cash Scripts
- Cash Scripts (Avoid PA)
- Data entry differences



# Current SEMPP Work/Projects

- › Patient referral when prescriber reporting to be charging cash for office visits- MCO's contacting patients
- › Cancer patients vs. Post-treatment Pain
- › Treatment of underlying disease (RA, psoriatic arthritis, ankylosing spondylitis)
- › CDC PfS Evaluation- Collaboration with BOP to evaluate program with PDMP data
- › CDC NOFO application for grant renewal

